33 Followers USX:VRTX - Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Inc
Sector: Health Care, Industry: Biotechnology

Add to Watchlist

•  Default
• New Watchlist

   

Yahoo Finance (Live Price)

• Summary
• Financials
• Dividend
• Prices
• Posts
• User
• Alerts
• Charts
• Options

Balance Sheet Cash Flow Income Statement Key Ratios Personalized

Show %	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	Graph
Total Revenue	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	7.57B 22.1%	8.93B 17.9%	9.87B 10.5%
Cost of Revenue	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	904.2M 22.8%	1.08B 19.5%	1.26B 16.8%
Gross Profit	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	6.67B 22.0%	7.85B 17.7%	8.61B 9.6%
Total Expenses	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	3.68B 10.4%	4.57B 24.0%	5.56B 21.8%
Operating Expense	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	2.78B 6.8%	3.48B 25.5%	4.3B 23.4%
Operating Income	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	3.89B 35.6%	4.37B 12.2%	4.31B -1.3%
Net Income (Cont Operations)	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	2.34B -13.6%	3.32B 41.8%	3.62B 9.0%
Net Income	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	2.34B -13.6%	3.32B 41.8%	3.62B 9.0%
Basic EPS	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	9.09 -12.9%	12.97 42.7%	14.05 8.3%
Diluted EPS	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	9.01 -12.4%	12.82 42.3%	13.89 8.3%